Danish pharma company seeks $13 million asset sale amid US class action

A Copenhagen-based biopharmaceutical company is set to sell its assets to US pharma group KemPharm as part of a restructuring announced last week, after failing to secure European approval to market a new drug.

Get unlimited access to all Global Restructuring Review content